Citations

Clear

4207 citation(s) found for "Chen, Bo".

Darier disease—A review highlighting new insights from the Darier Disease International Task Force
Labbouz, Sofia , Xiong, Grace , Murrell, Dedee Frances, Mueller, Simon M. , Mohandesi, Nessa Aghazadeh, Aldhaheri, Ahmed Salem, Asayag, Nissim, Baselga, Eulalia, Nadler, Chen , Chu, Chia‐Yu , Edminister, John R. , Guenova, Emmanuella, Gönülal, Melis , Gostynski, Antoni, Gupta, Lalit Kumar, Mazereeuw‐Hautier, Juliette, Hoetzenecker, Wolfram , Itin, Peter, Jankowski, Marek , Medvecz, Márta, Moosbrugger‐Martinz, Verena , Paller, Amy S., Plázár, Dóra , Queiróz, Amadeu José Rodrigues , Riera‐Monroig, Josep , Rosa, Ralph, Schmuth, Matthias, Freire, Maella Severino , Shabat, Itzhak, Shapiro, Jonathan , Soto‐García, Diego , Stratigos, Alexander J., Tadini, Gianluca Abel, Takeichi, Takuya , Verma, Kaushal K. , Wikström, Jakob D. , Ziv, Michael , Dodiuk‐Gad, Roni Pircha, Xiong, Grace , Mueller, Simon M , Ezzedine, Khaled , Choate, Keith , Gostynski, Antoni , Gupta, Ankan , Hoetzenecker, Wolfram , Jankowski, Marek , Kubo, Akiharu , Lee, Haur Yueh , Lehman, Julia Scott, Mellerio, Jemima E , Queiróz, Amadeu José Rodrigues , Freire, Maella Severino , Shapiro, Jonathan , Soto-García, Diego , Takeichi, Takuya , Wikström, Jakob D , Zink, Alexander , Navarini, Alexander , Hovnanian, Alain , Murrell, D F , Aghazadeh, Nessa , Aldhaheri, Ahmed S., Guenova, Emmanuella , Gönülal, Melis , Mazereeuw‐Hautier, J. , Lehman, Julia S. , Lepekhova, Anfisa A. , Medvecz, Márta, Paller, Amy S. , Schmuth, Matthias , Simpson, Cory L. , Tadini, Gianluca , Wikström, Jakob D. , Dodiuk‐Gad, Roni P.

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | June 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/jdv.70483 | PMID 42223188 Get It

Abstract Darier disease (DD) is a rare autosomal dominant genodermatosis. This comprehensive review, developed by the Darier Disease International Task Force (DDITF), consolidates current knowledge on the genetic basis, molecular pathophysiology, clinical presentation, diagnosis and management of DD, offering a global perspective that unites shared expertise. The disease arises from pathogenic variants in the ATP2A2 gene, which encodes sarco/endoplasmic reticulum Ca 2+ ‐ATPase isoform 2 (SERCA2), leading to disrupted calcium homeostasis and impaired desmosomal integrity. Clinically, DD is classified based on lesion type (classic vs. non‐classic) and is often accompanied by significant extracutaneous manifestations. Management remains challenging and requires a multifaceted approach, including topical therapies, systemic retinoids and lifestyle modifications. Emerging treatments that target the underlying molecular mechanisms offer promise for improved outcomes. This review aims to provide an updated reference and practical guidance for clinicians involved in the care and study of DD.
Colchicine Directly Targets Aldehyde Dehydrogenase 2 (ALDH2) to Suppress Radiation-Induced Senescence and Atherosclerosis
Abe, Jun‐ichi , Samanthapudi, Venkata Subrahman K, Chen, Weiqing , Tra, Ngoc Tuyet , Mejia, Gilbert F. , Hoang, Oanh, Rivera, Luis Antonio, Chu, Kun Yuan, Osawa, Masaki, Kim, J, Ko, Kyung Ae , Reddy, Anilkumar K. , Moreno, Silvia Fernanda López, Lenz, S., Mendoza, Keila Carolina Ostos , Sanchez, Edgardo, Herrmann, Joerg , Schadler, Keri , Manisty, Charlotte, Yusuf, Syed Wamique , Pathania, Rajneesh , Nead, Kevin T. , Hildebrandt, Michelle, Fuller, C David, Lin, Steve H., Le, Nhat‐Tu , Manisty, Charlotte , Hoang, O.N. , Kim, Jung Hyun , Hoang, Oanh , Abe, Jun-Ichi , Chen, Weiqing , Rivera, Luis Antonio , Kim, Jung Hyun , Lee, Jonghae , Li, Shengyu , Lenz, Stefania Assunto , Herrmann, Joerg , Schadler, Keri , Yvan-Charvet, Laurent , Ameri, Pietro , Yusuf, Syed Wamique , Burks, Jared K , Palaskas, Nicolas L , Fuller, Clifton D. , Koutroumpakis, Efstratios , Krishnan, Sunil , Wang, Guangyu , Kotla, Sivareddy

Mayo Clinic

No container title available | May 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.25.726409 Get It

Abstract Background Ionizing radiation (IR) accelerates atherosclerosis through induction of cellular senescence, DNA damage, defective efferocytosis, and dysregulation of clonal hematopoiesis (CH) drivers. Although low-dose colchicine reduces ischemic cardiovascular events in coronary artery disease, the precise molecular mechanisms underlying its vasculoprotective effects remain incompletely defined, and whether it mitigates radiation-associated vascular injury is unknown. Methods Bone marrow–derived macrophages (BMDMs) were pretreated with low-dose colchicine and exposed to 2 Gy IR. Molecular effects were assessed by RNA-seq, immunoblotting, and molecular docking. In vivo effects were tested in a partial carotid ligation (PLCL) model using spatial proteomics. Human monocyte-derived macrophages (HMDMs) from thoracic malignancy patients were analyzed before and after radiation therapy (RT). Results Low-dose colchicine suppressed IR-induced macrophage senescence signaling while preserving NRF2 activity. In a cell-free assay, colchicine directly activated aldehyde dehydrogenase 2 (ALDH2) in a dose-dependent manner (EC 50 1–5 nM), identifying ALDH2 as a direct molecular target of colchicine. Following irradiation, colchicine restored ALDH2, reduced mitochondrial (mt)ROS - dependent p90 ribosomal S6 kinase ( p90RSK ) activation and lipid peroxidation, preserved TET2 and DNMT3A expression, and rescued impaired efferocytosis while preventing nicotinamide adenine dinucleotide (NAD⁺) and adenosine triphosphate (ATP) depletion. These protective effects were ALDH2-dependent, as they were lost with ALDH2 inhibition or depletion and were mimicked by pharmacologic ALDH2 activation. In vivo, colchicine attenuated radiation-induced atherosclerosis and macrophage senescence-associated stemness (SAS). Consistently, macrophages from patients after RT showed reduced ALDH2 with increased mtROS, lipid peroxidation, and senescence. Conclusion These findings identify ALDH2 as a previously unrecognized molecular target of colchicine that links mitochondrial redox control to suppression of radiation-induced macrophage senescence and atherosclerosis and may contribute to the efficacy of low-dose colchicine in cardiovascular disease.
Dose-dependent white matter changes associated with repetitive head impacts in former American football players
Arciniega, Hector , Wickham, Alana, Szekely, Brian, Kim, Nicholas, Cho, Kang I, Carrington, Holly, Knyazhanskaya, Evdokiya , John, Omar , Jung, Leonard , Breedlove, Katherine M. , Mirmajlesi, Anya S, Stearns, Jared, Rushmore, R Jarrett, Daneshvar, Daniel H, Wiegand, Tim L T, Billah, Tashrif , Pasternak, Ofer, Cetin-Karayumak, Suheyla, Rathi, Yogesh, Coleman, Michael J, Bernick, Charles, Balcer, Laura J, Im, Brian , Datta, Shae , Alosco, Michael L. , Lin, Alexander P, Cummings, Jeffrey L, Reiman, Eric M, Stern, Robert A, Shenton, Martha E, Bouix, Sylvain, Su, Yi, Chen, Kewei, Protas, Hillary, Boker, Connie, Au, Rhoda, Cantu, Robert C, Farrer, Lindsay, Helm, Robert, Katz, Douglas I, Kowall, Neil, Mez, Jesse, Mercier, Gustavo, Otis, James, Weller, Jason, Simkin, Irene, Andino, Alondra, Conneely, Shannon, Diamond, Courtney, Fagle, Tessa, Haller, Olivia, Hunt, Tennyson, Gullotti, Nicole, Mariani, Megan, Mayville, Brian, McLaughlin, Kathleen, Nanna, Mary, Platt, Taylor, Rice, Fiona, Sestak, Madison, McClean, Michael, Tripodis, Yorghos, Annis, Douglas, Chaisson, Christine, Dixon, Diane, Finney, Carolyn, Gallagher, Kerrin, Hartlage, Kaitlin , Lu, Jun, Martin, Brett, Ojo, Emmanuel, Palmisano, Joseph N, Pine, Brittany, Ramachandran, Janani, Fitzsimmons, Jennifer, Arcinieago, Hector, Bonke, Elena, Coello, Eduardo , Jung, Leonhard, Liao, Huijun, Loy, Maria, Rizzoni, Elizabeth, Schultz, Vivian , Silva, Annelise, Vessey, Brynn, Banks, Sarah, Miller, Jason, Ritter, Aaron , Sabbagh, Marwan, Cruz, Raelynn de la, Durant, Jan, Golceker, Morgan, Harmon, Nicolette, Kaylegian, Kaeson, Long, Rachelle, Nance, Christin, Sandoval, Priscilla, Serrano, Andrew, Dodick, David W, Geda, Yonas, Wethe, Jennifer V, Falk, Bryce, Duffy, Amy, Howard, Marci, Montague, Michelle , Osgood, Thomas, Babcock, Debra, Bellgowan, Patrick, Balcer, Laura, Barr, William, GOLDBERG, JUDITH, Wisniewski, Thomas, Kirov, Ivan, Lui, Yvonne, Marmar, Charles, Hasanaj, Lisena, Serrano, Liliana , Al-Kharafi, Alhassan, George, Allan, Martin, Sammie, Riley, Edward, Runge, William, Peskind, Elaine R. , Colasurdo, Elizabeth , Marcus, Daniel S, Gurney, Jenny , Greenwald, Richard, Johnson, Keith A, Wethe, Jennifer V. , Wiegand, Tim L. T. , Jung, Leonard B , Breedlove, Katherine , Stearns, Jared , Adler, C H , Alosco, Michael L , Koerte, Inga K , Wethe, Jennifer V , Arciniega, Hector , Kim, Nicholas , Carrington, Holly , Rushmore, R. Jarrett , Daneshvar, Daniel H. , Pasternak, Ofer , Karayumak, Suheyla Cetin , Rathi, Yogesh , Coleman, Michael J. , Adler, Charles H. , Bernick, Charles , Balcer, Laura J. , Reiman, Eric M. , Shenton, Martha E. , Bouix, Sylvain , Protas, Hillary , Cantu, Robert C. , Katz, Douglas I. , Mez, Jesse , Weller, Jason , Fagle, Tessa, Mariani, Megan, McLaughlin, Kathleen , Pulukuri, Surya Vamsi , Sestak, Madison, McClean, Michael D , Tripodis, Yorghos , Annis, Douglas, Finney, Carolyn, Palmisano, Joseph , Pine, Brittany, Ramachandran, Janani , Bonke, Elena M. , Liao, Huijun, II, Robert W. Turner , Marek, Kenneth , Dodick, David W. , Geda, Yonas E. , Howard, Marci, Montague, Michelle, Babcock, Debra, Bellgowan, Patrick S.F. , Barr, William , Kirov, Ivan, George, Allan, Colasurdo, Elizabeth A. , Marcus, Daniel S., Johnson, Keith A.

Mayo Clinic

Brain Communications | May 29, 2026 | Volume: 8 | Issue: 3 | Pages: No page available

10.1093/braincomms/fcag195 | PMID 42293319 Get It

Abstract Repetitive head impacts sustained during American football have been associated with neuropathological changes such as white matter shear injuries. However, the impact of specific factors, such as age of first exposure and cumulative head impact burden, on white matter integrity remains unclear. This study investigated in vivo white matter microstructural changes using diffusion tensor imaging and tract-based spatial statistics in 165 male former American football players (mean age 57.3 years, range 45–74) and 52 unexposed asymptomatic male controls (mean age 59.4 years, range 45–74) in the DIAGNOSE CTE Research Project. Compared to controls, former football players exhibited significantly higher fractional anisotropy (FA) in 1.97% of the white matter skeleton (1552 voxels; Cohen’s d = 0.587) and higher tissue-corrected FA (FAt) in 1.48% of the white matter skeleton (1004 voxels; Cohen’s d = 0.616). No significant differences were observed for mean diffusivity, axial diffusivity, radial diffusivity, or free water between football players and controls. Among football players, there were no significant differences in the white matter microstructure between players diagnosed with traumatic encephalopathy syndrome and those without the diagnosis. Lower FA was significantly associated with older age (P < 0.00001) and an earlier age of first exposure to tackle football (P < 0.01), while lower FAt was associated with greater cumulative head impact burden, specifically higher linear acceleration (P < 0.04) and rotational force (P < 0.02). This study highlights the influential role of exposure factors on white matter microstructure in former American football players, as well as the utility of diffusion tensor imaging to aid in characterizing the long-term effects of repetitive head impacts in contact sport athletes.
Transplantation of older DCD livers in the machine perfusion era: a U.S. cohort study
Ziogas, Ioannis A., Moris, Dimitrios, Theocharopoulos, Charalampos , Yoeli, Dor, Adams, Megan A., Barbas, Andrew S. , Montenovo, Martin I. , Chen, M G, Kapoor, Sorabh , Calderon, Esteban , Moon, Andrew M., Deutch-Link, Sasha, Shroff, Hersh , Barritt, A. Sidney, Mathur, Amit K., Nydam, Trevor, Desai, Chirag S., Schegel, Andrea, Chen, Melissa, Shah, Neil D, Giorgakis, Emmanouil , Ziogas, Ioannis A. , Varvoglis, Dimitrios N. , Yoeli, Dor , Adams, Megan A. , Moon, Andrew M , Deutsch‐Link, Sasha , Shah, Neil , Fix, Oren K. , Barritt, A. Sidney, Nydam, Trevor L. , Desai, Chirag S., Martins, Paulo N.

Mayo Clinic

Transplant International | May 29, 2026 | Volume: 39 | Issue: No issue available | Pages: No page available

10.3389/ti.2026.16689 | PMID 42294094 Get It

Donation after circulatory death (DCD) livers increasingly use machine perfusion (MP). This study evaluates MP’s impact on older DCD livers based on data from the United Network for Data Sharing, covering all first adult DCD liver transplants (2016–2025). The cohort, divided into pre-MP and MP eras (separated by the FDA approval of the first normothermic MP platform in 2021), showed accelerated growth in DCD liver transplants during the MP era. Donors ≥60 rose 7.8-fold, including donors ≥70 (a USA first). By 2025, DCD livers accounted for 43.2%, with 61.35% from donors ≥50. Normothermic regional perfusion (NRP) (3.0%–21.7%), NMP (2.3%–35.6%), and sequential NRP-NMP (0.1%–19.2%) increased significantly (p < 0.001). The MP era was associated with a decrease in median waitlist time from 112 to 62 days (p < 0.001). Early graft survival was similar across ages. For ages 50–59, 1- and 3-year survivals were 87.9%/78.4% pre-MP and 90.1%/78.8% in the MP era. For 60–69, survival was 85.0%/80.6% pre-MP and 90.0%/71.3% in the MP era. DCD LTs for ≥70 were limited to the MP era with 87.8% 1-year survival. Multivariable Cox regression showed that static cold storage (HR = 1.19), donor age 50–69 versus 18–49, and recipient age (HR = 1.04) increased the risk of graft loss after adjustment. MP is associated with an increased number of older DCD liver transplants and acceptable early graft survival.
ROCKET-CLL: A randomized, open-label, multicenter, phase 3 study of rocbrutinib (LP-168) versus pirtobrutinib in covalent BTK inhibitor (cBTKi) in pretreated relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Chen, Anna, Woyach, Jennifer A. , Seymour, John F. , Brander, Danielle M., Tan, Fenlai , Anthony, Stephen P. , Shang, Kewei, Shen, Yue, Lou, Yejiang, Byrd, John C., Brander, Danielle M. , Stephens, Deborah M. , Kay, Neil E. , Chen, Yi, Byrd, John C.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps7100 Get It

TPS7100 Background: Bruton tyrosine kinase covalent inhibitors (cBTKi) have been transformative in CLL treatment. Despite achieving extended remissions, in most patients disease still relapses despite cBTKi therapy, often associated with BTK C481 mutations. Non-covalent BTKi (ncBTKi), including pirtobrutinib, can overcome this resistance (Sharman et al. ASCO . 2025). Pirtobrutinib received FDA approval in Dec 2025, for R/R CLL/CLL patients pretreated with cBTKi. Rocbrutinib (LP-168) is a highly selective next-generation BTKi that can covalently bind wild-type and gatekeeper mutations (T474X, commonly seen in patients relapsed after pirtobrutinib) and non-covalently target C481-mutated BTK , with preclinical efficacy in treatment-naïve and BTKi-resistant CLL (Gordon et al. IWCLL . 2025). In the rocbrutinib phase 1 trial (NCT04775745), encouraging safety and efficacy have been observed in CLL patients with prior exposure to BTKi and/or BCL2 inhibitor (BCL2i) (Woyach et al. Blood. 2025). Presented here is the design of a phase 3 trial aiming to compare the efficacy of rocbrutinib versus pirtobrutinib in cBTKi-pretreated R/R CLL/SLL patients. Methods: ROCKET-CLL (NCT07342478) is a randomized, open-label, multicenter, phase 3 study comparing rocbrutinib (Arm 1) to pirtobrutinib (Arm 2) in R/R CLL/SLL subjects who previously received treatments including covalent BTKi. Eligible subjects must require treatment per 2018 iwCLL criteria, have measurable lesions by CT, an ECOG performance score of 0-2, and adequate hematologic and other organ functions. About 306 subjects will be randomized 1:1 based on stratification factors such as 17p deletion/ TP53 mutation presence, reasons for discontinuing prior cBTKi, prior BCL2i treatment, and geographic region. Participants assigned to each arm will receive rocbrutinib (200 mg QD) or pirtobrutinib (200 mg QD) tablets continuously until disease progression, unacceptable toxicity, withdrawal, or other study discontinuation criteria are met. The primary endpoint is progression-free survival (PFS), assessed by an independent review committee (IRC) per iwCLL 2018 criteria with CLL (Hallek et al. 2018) and Lugano 2014 criteria with SLL (Cheson et al. 2014). Important secondary endpoints include overall survival (OS), time to next treatment (TTNT), event-free survival (EFS), overall response rate (ORR), duration of response (DOR), PFS assessed by investigator (INV), concordance between IRC and INV PFS, safety and tolerability, and population PK. Exploratory endpoints include health-related quality of life and biomarker assessment. Recruitment is ongoing. Clinical trial information: NCT07342478 .
Symbiotic-GI-03: A randomized, double-blind, phase 3 study of first-line PF-08634404, a PD-1/VEGF bispecific antibody, in combination with mFOLFOX6 in patients with metastatic colorectal cancer (mCRC).
Elez, E, Taieb, Julien, Xu, Rui-Hua, Taniguchi, Hiroya, Bekaii-Saab, Tanios S., Tie, Jeanne, Chalabi, Myriam , Chen, Zhiyu, Opneja, Aman, Kochenderfer, Mark D., Hong, Yong Sang , Richards, Donald A., Radecka, B., Clancy, Jill, Tonkovyd, Svitlana, Zhang, Xiaosong, Ng, Kimmie, Eng, Cathy , Élez, Elena , Taı̈eb, Julien , Xu, Rui‐Hua , Taniguchi, Hiroya , Bekaii‐Saab, Tanios , Tie, Jeanne , Chen, Zhiyu , Richards, D., Chen, Yiyi , Clancy, Jill S., Zhang, Xiaosong, Ng, Kimmie

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps3675 Get It

TPS3675 Background: Multi-agent chemotherapy regimens (eg, mFOLFOX6) ± anti-vascular endothelial growth factor (VEGF) or anti-epidermal growth factor regimens are currently the standard of care for patients (pts) with mCRC without targetable mutations. However, the 5-year survival rate remains low at approximately 16% (SEER, 2025). The addition of biological therapies (eg, bevacizumab [bev], an anti-VEGF monoclonal antibody) to immune checkpoint inhibitors (ICIs) has demonstrated a synergistic antitumor effect in solid tumors. However, ICI monotherapy has limited activity in mismatch repair proficient (pMMR)/microsatellite stable (MSS) mCRC. Simultaneous bispecific targeting of programmed death 1 (PD-1) and VEGF in conjunction with cytotoxic chemotherapy has the potential to enhance antitumor activity. PF-08634404 is a fully human immunoglobulin G4 (IgG4) bispecific antibody targeting PD-1 and VEGF. A phase 2 study of PF-08634404 with XELOX or mFOLFOX6 demonstrated promising antitumor activity with a manageable safety profile in first-line (1L) mCRC (Xu X, ESMO 2025; Abstract 796P). Methods: Symbiotic-GI-03 (NCT07222800) is an ongoing, double-blind, randomized, phase 3 study evaluating the efficacy and safety of 1L PF-08634404 + mFOLFOX6 vs bev + mFOLFOX6. Inclusion criteria are age ≥18 y; mCRC with measurable disease per RECIST 1.1; no prior systemic therapy for metastatic disease; ECOG PS 0 or 1; and adequate hematologic, hepatic, and renal function. Pts with BRAF V600E-mutant or mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) CRC, active central nervous system metastases, or clinically significant risk of hemorrhage/fistula will be excluded. Approximately 800 pts will be randomized 1:1 to receive PF-08634404 + mFOLFOX6 or bev + mFOLFOX6 until disease progression, unacceptable toxicity, withdrawal of consent, or death. Randomization will be stratified by region (North America, Europe, or rest of world), RAS status (mutant or wildtype), and presence of liver metastasis (yes or no). The dual primary endpoints are progression-free survival (PFS) by blinded independent central review and overall survival; for each, a stratified log-rank test will be used to compare arms. Hazard ratios with corresponding 2-sided 95% CIs will be estimated using a stratified Cox proportional hazards model, and medians will be estimated using the Kaplan-Meier method with corresponding 2-sided 95% CIs calculated using the log(-log) method. Secondary endpoints include PFS by investigator, objective response rate, duration of response, PFS after next-line therapy, safety/tolerability, pharmacokinetics, immunogenicity, and patient-reported outcomes. Enrollment began in December 2025. Clinical trial information: NCT07222800 .
Timing of palliative care referral and overall survival in patients with melanoma brain metastases treated with ipilimumab and nivolumab.
Parker, Jefferson , ELANTABLY, DINA, Hamilton, Jakob Skyler, White, Donnell, Ashby, Frederick, Smith, AM, Chen, Ruqin, Elantably, Dina, Ashby, Fay, Smith, Alina

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e21607 Get It

e21607 Background: The association between timing of palliative care referral and survival outcomes in patients with melanoma brain metastases (MBM) treated with immune checkpoint inhibitors remains poorly characterized. Methods: We conducted a retrospective cohort study of patients with MBM treated with combination ipilimumab and nivolumab at Mayo 3 sites from 2016 to 2024. Palliative care referral timing relative to MBM diagnosis was categorized as early (≤56 days), late ( > 56 days), or none. Patients without referral documentation were excluded from referral-based analyses. Overall survival (OS) was estimated using Kaplan–Meier methods and compared with log-rank tests. Multivariable Cox proportional hazards models were used to identify factors independently associated with OS, with stepwise selection (entry p < 0.25; stay p < 0.15). Results: Among 147 patients, 139 had referral information: 33 (23.7%) early, 56 (40.3%) late, and 50 (36.0%) no referral. Median OS differed significantly by referral timing (log-rank p < 0.0001): 2.8 months (early), 7.9 months (late), and 47.8 months (no referral). Among patients with ECOG 2–3, a higher proportion had early or late referral (each 42.9%) compared with no referral (14.3%), whereas patients with ECOG 0–1 were more evenly distributed across referral groups (early 21.6%, late 40.0%, none 38.4%). In multivariable analysis of 88 patients with complete covariate data, both early (HR 4.54; p = 0.0016) and late referral (HR 2.86; p = 0.011) were independently associated with worse OS compared with no referral. Progressive disease versus objective response (HR 4.45; p = 0.0002), hemorrhagic metastases (HR 2.79; p = 0.0015), male sex (HR 2.07; p = 0.044), and increasing age (HR 1.02 per year; p = 0.032) were also associated with inferior OS. Treatment with ipilimumab 1 mg/kg plus nivolumab 3 mg/kg showed a trend toward improved OS compared with ipilimumab 3 mg/kg plus nivolumab 1 mg/kg (HR 0.48; p = 0.055). Conclusions: Timing of palliative care referral was strongly associated with overall survival in patients with MBM treated with ipilimumab and nivolumab. Although patients with ECOG 2–3 were more frequently referred early or late, ECOG category overall did not clearly differentiate referral timing groups, suggesting referral may reflect unmeasured clinical factors beyond baseline performance status. Prospective studies incorporating more granular functional and symptom measures are needed to better define the role of palliative care integration in this population. Multivariable cox model for overall survival. Variable Comparison HR P value Referral timing Early vs None 4.54 0.0016 Late vs None 2.86 0.011 Best overall response PD vs ORR 4.45 0.0002 SD vs ORR 2.16 0.098 Hemorrhagic metastases Yes vs No 2.79 0.0015 Sex Male vs Female 2.07 0.044 Age Per year increase 1.02 0.032 Regimen Ipi1+Nivo3 vs Ipi3+Nivo1 0.48 0.055
National patterns of overtreatment in low-risk and undertreatment in high-risk prostate cancer and associated survival impact.
Jain, Pragya , Abdelhakeem, Ahmed, Ganatra, Nency, Adeoye, Oluwatayo , Patel, Shivam Chetankumar, Patel, Ansy , Patel, Manan , Hamilton, Jakob Skyler, Hou, Alicia, Chen, Ruqin , Tan, Winston, Kase, Adam M. , Ganatra, Nency, Tan, Winston

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e17027 Get It

e17027 Background: Guidelines recommend active surveillance for low-risk prostate cancer and definitive therapy for high-risk disease. We evaluated national patterns of risk-misaligned care and the survival consequences of undertreatment. Methods: National Cancer Database prostate cancer cases diagnosed from 2010–2022 were analyzed. Low-risk disease was defined as clinical T1–T2, Grade Group 1, and PSA < 10; overtreatment was definitive treatment vs active surveillance or no treatment. High-risk disease was defined as Grade Group ≥4, PSA ≥20, or clinical T3–T4; undertreatment was no definitive local therapy or incomplete definitive therapy. Multivariable logistic regression evaluated factors associated with misalignment. Overall survival (OS) among high-risk patients was assessed using multivariable Cox regression. Results: Among low-risk patients (N = 124,562), overtreatment occurred in 40% of cases. Overtreatment was more common among young men (adjusted odds ratio [aOR] 0.982; p < 0.001) and less common at academic centers (aOR 0.414; p = 0.015). Compared with White men, odds of overtreatment were lower among Black men (aOR 0.946; p = 0.002) and Asian men (aOR 0.827; p < 0.001), with additional variation by education and region (all p < 0.001). Among high-risk patients (N = 318,532), undertreatment affected 27.3% of patients and was more common among older men (aOR 1.061; p < 0.001). Compared with White men, undertreatment was higher among Black men (aOR 1.479; p < 0.001) and lower among Asian patients (aOR 0.863; p < 0.001) (overall race p < 0.001). Compared with private insurance, undertreatment was higher in Medicaid (aOR 2.038; p < 0.001) and uninsured patients (aOR 2.649; p < 0.001), and slightly lower with Medicare (aOR 0.931; p < 0.001) (overall insurance p < 0.001). Multiple comorbidities were associated with higher undertreatment (≥2 vs 0: aOR 1.252; p < 0.001). Facility type was not independently associated (p = 0.490), while region remained significant (overall p < 0.001). In the survival cohort (high risk) (N = 338,919), undertreatment was associated with substantially worse OS (HR 2.745, 95% CI 2.706–2.784; p < 0.001), adjusted for age (HR 1.056; p < 0.001), race (p = 0.001), insurance (p < 0.001), comorbidity (p < 0.001), income (overall p < 0.001), education (overall p < 0.001), and facility region (overall p < 0.001). Conclusions: Low-risk overtreatment remains common nationwide and varies across patient and health-system factors. In high-risk disease, undertreatment affects over one-quarter of patients and disproportionately impacts Black men and those with Medicaid or no insurance. Undertreatment confers a nearly threefold mortality hazard (adjusted HR 2.75; p < 0.001), highlighting a major national quality gap and the urgent need for system-level interventions to ensure equitable, guideline-concordant delivery of definitive therapy.
Real-world comparison of atezolizumab/bevacizumab vs durvalumab/tremelimumab in decompensated hepatocellular carcinoma.
Chen, Yuhan , Ng, Wee Han , Chiang, Ting‐Hsuan , Kaymen, Emily, Rastogi, Natasha, Tran, Nguyen H., Yang, Ju Dong, Kaymen, Emily A. , Rastogi, Natasha, Tran, Nguyen H., Yeo, Yee Hui

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e16159 Get It

e16159 Background: Pivotal trials established atezolizumab-bevacizumab and durvalumab-tremelimumab as first-line therapies for unresectable hepatocellular carcinoma (HCC). Atezolizumab plus bevacizumab demonstrated superior survival outcomes compared to sorafenib for unresectable HCC in the IMbrave150 trial in 2020, while durvalumab plus tremelimumab showed superior survival in the HIMALAYA trial in 2022. However, data on head-to-head comparison of these two combinations as first-line systemic therapy for the patient with decompensated HCC are limited. This study aims to compare survival outcomes between these two treatment regimens in decompensated HCC patients to address a critical gap in the current literature, as decompensated patients have largely been excluded from clinical trials. Methods: This retrospective study utilized electronic health records from 146 U.S. healthcare organizations within the TriNetX Network. Adults aged ≥21 years diagnosed with decompensated HCC receiving atezolizumab/bevacizumab and durvalumab/tremelimumab from 10/21/2022 to 8/20/2024 were included. The comparison group received atezolizumab/bevacizumab, and the control group received durvalumab/tremelimumab. The primary outcome was all-cause mortality. A 1:1 propensity score matching was conducted to balance baseline characteristics (age, gender, race/ethnicity, lab results including liver function tests, platelet counts, INR, gamma glutamyl transferase, alpha-fetoprotein, and underlying liver diseases). Kaplan–Meier survival analysis and Cox regression was used to estimate the mortality risk. Subgroup analysis was stratified by HCC etiology. Results: A total of 302 and 664 patients received durvalumab/tremelimumab, atezolizumab/bevacizumab, respectively. After propensity matching, 253 patients per group were included. Median OS was 283 days with durvalumab/tremelimumab and 391 days with atezolizumab/bevacizumab. The two treatment regimens showed no significant difference in survival (hazard ratio [HR]: 0.875, 95% confidence intervals [CI] 0.696–1.101, p=0.254). Subgroup analyses demonstrated no significant differences in survival between the two groups of patients in MASLD (HR: 0.698, 95% CI: 0.468–1.040), alcohol associated liver disease (HR: 0.821, 95% CI: 0.603–1.118), and chronic viral hepatitis (HR: 0.852, 95% CI: 0.596–1.219). Conclusions: There was no statistically significant difference in survival outcomes between atezolizumab plus bevacizumab and durvalumab plus tremelimumab in patients with decompensated advanced HCC. These results support current real-world practice in which both regimens may be considered viable first-line treatment options in this high-risk population with liver decompensation.
Platinum chemotherapy and oncolytic virotherapy as used to cooperatively sustain stem-like CD8⁺ T-cell immunity via type I interferon modulation.
Yang, Vivienne , Dong, Zhongyi , Liu, T J, 郭其森, Zhang, H Z, Ni, Bo, Bai, Long, Chen, Yiwen, Zong, Jiasheng, Xia, Xiang, Zheng, Jiaojiao, Pham, Hoang Tran , Parker, Jefferson , Morecroft, Renee, Elalfy, Aya, Ingram, Demarcus, Abdel-Hakeem, Ahmed, Ali, Muhammad, Ni, Bo , Bai, Long, Xia, Xiang, Pham, Hoang Tran, Morecroft, Renée , Elalfy, Aya, Prada, Libardo Rueda , Ali, Muhammad, Zhang, Zizhen

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e14545 Get It

e14545 Background: Durable antitumor immunity depends on the maintenance of stem-like CD8⁺ T cells capable of sustaining long-term effector responses. Oncolytic viruses (OVs) are potent immunomodulatory agents that reshape the tumor microenvironment and augment antitumor immunity. We hypothesized that platinum-based chemotherapy alters tumor-intrinsic type I interferon (IFN-I) signaling in a manner that can be functionally restored by OV therapy, thereby promoting the generation and persistence of stem-like CD8⁺ T cells. Methods: Tumor cells treated with platinum chemotherapy were evaluated in vitro for changes in IFN-I pathway activity, OV replication, and markers of immunogenic cell death (ICD). Syngeneic mouse tumor models were used to assess antitumor efficacy and immune remodeling following combination therapy. Tumor-infiltrating lymphocytes were analyzed by single-cell RNA sequencing and multiparameter flow cytometry to define CD8⁺ T-cell states and functional programs. Guided by these preclinical findings, a clinical trial combining XELOX, PD-1 blockade, and OV therapy was initiated (ChiCTR2500107607). Results: Platinum chemotherapy significantly suppressed tumor-intrinsic IFN-I signaling, while OV therapy restored antiviral responses, enhanced viral replication, and increased ICD in vitro. In vivo, the combination strategy resulted in superior tumor control and profound remodeling of the tumor immune microenvironment. The most pronounced immunologic effect was observed within the stem-like CD8⁺ T-cell compartment. Combination therapy induced a distinct population of TCF7⁺ ISG15^high NFATC1^low AP-1^low CD8⁺ T cells, characterized by restrained activation, enhanced persistence, and reduced propensity toward terminal exhaustion. In IRF7-deficient tumors, this stem-like CD8⁺ T-cell population failed to emerge and antitumor efficacy was significantly diminished, indicating that moderate tumor-intrinsic IFN-I signaling is required for this immune state. Conclusions: Tumor-intrinsic type I interferon signaling is a critical determinant of synergy between platinum chemotherapy and oncolytic virotherapy, enabling the maintenance of durable stem-like CD8⁺ T-cell immunity. These findings establish a mechanistic rationale for combining platinum chemotherapy, oncolytic viruses, and immune checkpoint blockade and support ongoing clinical translation. Clinical trial information: ChiCTR2500107607.